Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates

References

• Melton III LJ. How many women have osteoporosis now? J Bone Miner Res 1995;10:175–7
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation. America’s bone health: the state of osteoporosis and low bone mass in our nation. Washington (DC): National Osteoporosis Foundation; 2002
   Google Scholar
• Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporosis Int 2000;11:669–74
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. The frequency of bone disease. Bone health and osteoporosis. A report of the surgeon general. Rockville (MD): USDHHS; 2004. p. 68–87
   Google Scholar
• Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002:359;1761–7
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis JA, Oden A, et al. Mortality after osteoporotic fractures. Osteoporosis Int 2004;15:38–42
   PubMed Web of Science ®Google Scholar
• US Congress Office of Technology Assessment. Hip fracture outcomes in people age 50 and over: background paper. Washington (DC): Government Printing Office; 1994 [Report OTA-BP-H–120]
   Google Scholar
• National Osteoporosis Foundation. Fast facts on osteoporosis. Washington (DC): National Osteoporosis Foundation; 2005
   Google Scholar
• Lips P, van Schoor NM. Quality of life in patients with osteoporosis. Osteoporosis Int 2005;16:447–55
   PubMed Web of Science ®Google Scholar
• Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 2000;15:1384–92
   PubMed Web of Science ®Google Scholar
• Tosteson AN, Gabriel SE, Grove MR, et al. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporosis Int 2001;12:1042–1049
   PubMed Web of Science ®Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453–60
   PubMed Web of Science ®Google Scholar
• Gold DT, Cramer JA, Sunyecz JA, et al. Consistent improvement in bisphosphonate persistence with less frequent dosing: review comparing results of three databases. Abstract presented at the 12th annual meeting of the international society for clinical densitometry, San Diego, California, February 1, 2006
   Google Scholar
• Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856–61
   Google Scholar
• Huybrechts KF, Ishak KJ, Proskorovsky I, et al. Persistence and compliance with bisphosphonate therapy among postmenopausal osteoporotic women: a comparison between daily and weekly regimens. J Bone Miner Res 2005;20:S397
   Web of Science ®Google Scholar
• Weycker D, Macarios D, Oster G. Adherence with weekly versus daily bisphosphonate therapy among women with postmeno pausal osteoporosis. J Bone Miner Res 2005;20:S280
   Google Scholar
• Penning-van Beest FJ, Goettsch WG, Erkens JA, et al. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006;28:236–42
   Google Scholar
• Sambrook P. Compliance with treatment in osteoporosis patients – an ongoing problem. Aust Fam Physician 2006;35:135–7
   PubMedGoogle Scholar
• Chesnut CH, III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–9
   PubMed Web of Science ®Google Scholar
• Cooper A, Drake J, Brankin E, the PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;1–10
   Google Scholar
• Johnell O, Jonsson B, Jonsson L, et al. Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003;21:305–14
   PubMed Web of Science ®Google Scholar
• Schousboe JT, Nyman JA, Kane RL, et al. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005;142:734–41
   PubMed Web of Science ®Google Scholar
• Stevenson M, Lloyd JM, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1–160
   PubMed Web of Science ®Google Scholar
• Grima DT, Burge RT, Becker DL, et al. Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture. P & T. 2002;27:448–55
   Google Scholar
• Kanis JA, Brazier JE, Stevenson M, et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2002;6:1–146
   PubMedGoogle Scholar
• Mullins CD, Ohsfeldt R. Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. J Manag Care Pharm 2003;9:150–8
   PubMedGoogle Scholar
• Zethraeus N, Borgstrom, Strom O, et al. Cost-effectiveness of the treatment and prevention of osteoporosis – a review of the literature and a reference model. Osteoporosis Int 2007;18:9–23
   PubMed Web of Science ®Google Scholar
• Tosteson AN, Jonsson B, Grima DT, et al. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporosis Int 2001;12:849–57
   PubMed Web of Science ®Google Scholar
• Coyle D, Cranney A, Lee KM, et al. Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane collaboration methods for meta-analysis within economic evaluation. Pharmacoeconomics 2001;19:565–75
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [Fracture Intervention Trial Research Group]. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis [Vertebral Efficacy with Risedronate Therapy (VERT) Study Group]. Osteoporosis Int 2000;11:83–91
   PubMed Web of Science ®Google Scholar
• Census 2000 Summary File 1 (SF 1) 100-percent data. Sex by age (49) – universe: total population [p. 12]. Washington (DC): US Census Bureau; 2000. Available at: http://factfinder.census.gov/servlet/STTable?_bm=y&-geo_id=01000US&-qr_name=ACS_2005_EST_G00_S0101&-ds_name=ACS_2005_EST_G00_ [last accessed 12 February 2007]
   Google Scholar
• O’Neill TW, Felsenberg D, Varlow J, et al. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996;11:1010–8
   Google Scholar
• Looker AC, Orwoll ES, Johnson CC, et al. Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 1997;12:1761–8
   PubMed Web of Science ®Google Scholar
• Black DM, Palermo L, Grima DT. Developing better economic models of osteoporosis: considerations for the calculation of the relative risk of fracture. Value Health 2006;9:54–8
   Google Scholar
• Cooper C, Atkinson EJ, O’Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. J Bone Miner Res 1992;7: 221–7
   Google Scholar
• Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721–39
   PubMed Web of Science ®Google Scholar
• Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315–22
   PubMed Web of Science ®Google Scholar
• Ravn P, Clemmesen B, Riis BJ, et al. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996;19:527–33
   PubMed Web of Science ®Google Scholar
• Riis BJ, Ise J, von Stein T, et al. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001;16:1871–8
   PubMed Web of Science ®Google Scholar
• Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis [Alendronate Once-Weekly Study Group]. Aging (Milano) 2000;12:1–12
   PubMedGoogle Scholar
• Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103–11
   PubMed Web of Science ®Google Scholar
• Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051–6
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002 87:1586–92
   PubMed Web of Science ®Google Scholar
• Zaidi M, Friend K, Epstein S. Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans. Ann NY Acad Sci. 2006;1068:560–3
   Google Scholar
• Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004;20:433–9
   PubMed Web of Science ®Google Scholar
• Bagger YZ, Tanko LB, Alexandersen P, et al. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 2003;33:301–7
   PubMed Web of Science ®Google Scholar
• Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. New Engl J Med 2004;350:1189–99
   PubMed Web of Science ®Google Scholar
• Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999;131:935–42
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporosis Int 1998;8:S7–S80
   PubMedGoogle Scholar
• Consumer price index – all urban consumers (current series). Washington (DC): US Department of Labor/Bureau of Labor Statistics; 2006. Available at: http://data.bls.gov/PDQ/outside.jsp?survey=cu [last accessed 8 February 2007]
   Google Scholar
• Red Book for Windows [computer program]. Version 61127. Greenwood Village, CO: Thompson PDR, 2005
   Google Scholar
• Bobba RS, Beattie K, Parkinson B, et al. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf 2006;29:1133–52
   PubMed Web of Science ®Google Scholar
• Brazier JE, Green C, Kanis JA. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporosis Int 2002;13:768–76
   Google Scholar
• Centers for Disease Control and Prevention. Table 3: number of deaths and death rates, by age, race, and sex. Natl Vital Stat Rep 2003;52:21
   Google Scholar
• Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006;119:S18–S24
   PubMed Web of Science ®Google Scholar
• Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006;119:S12–S17
   PubMedGoogle Scholar
• Reginster JY. Adherence and persistence: impact on outcomes and health care resources. Bone 2006;38:S18-S21 [epub: 2006 January 27]
   Google Scholar
• Lynch NO, Walker M, Cowell W, et al. An international comparison of the impact of dosing frequency on adherence with bisphosphonate therapy among postmenopausal women in the UK and Germany. J Bone Miner Res 2005;20:S396
   Web of Science ®Google Scholar
• Fardellone P, Gaudin AF, Cotte FE, et al. Comparison of the persistence of daily and weekly bisphosphonates in French female patients treated for osteoporosis. J Bone Miner Res 2005;20 [Presentation SU416]
   Google Scholar
• Gold DT, McClung B. Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med 2006;119:S32–S37
   PubMedGoogle Scholar
• Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications among 40 000 Medicare beneficiaries. J Bone Miner Res 2005;20 [Presentation M371]
   Google Scholar
• Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:875–83
   PubMed Web of Science ®Google Scholar
• Stock JL, Bell NH, Chesnut III CH, et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997;103:291–7
   PubMed Web of Science ®Google Scholar
• Black DM, Schwartz AV, Ensrud KE, et al.; for the FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. J Am Med Assoc 2006;296: 2927–38
   Google Scholar
• Bauss F, Schimmer RC. Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Ther Clin Risk Manage 2006;2:3–18
   PubMedGoogle Scholar